Connexon Creative - Cord Blood News 2.24

Cord Blood News 2.24, June 24, 2010.

In this issue: Science News | Current Publications | Industry News | Policy News | Events

TOP STORY

Revised Map of the Human Progenitor Hierarchy Shows the Origin of Macrophages and Dendritic Cells in Early Lymphoid Development
Researchers provide a comprehensive analysis of the human hematopoietic hierarchy by clonally mapping the developmental potential of seven progenitor classes from neonatal cord blood and adult bone marrow. [Nat Immunol]

Learn about the benefits of MethoCult^® Express
for cord blood samples
by STEMCELL Technologies

WATCH THE VIDEO

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Modeling the Human 8p11-Myeloproliferative Syndrome in Mice
Researchers report that expression of ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) or BCR/FGFR1 in normal human CD34+ cells from umbilical cord blood leads to increased cellular proliferation and differentiation towards the erythroid lineage in vitro. [Blood]

Protein Kinase B (PKB/c-akt) Regulates Homing of Hematopoietic Progenitors Through Modulation of their Adhesive and Migratory Properties
Protein kinase B activity was found to be required for induction of adhesion to bone marrow derived stromal cells, and detrimental for migration of umbilical cord blood derived CD34+ hematopoietic progenitors. [Blood]

Cellular Reprogramming of Human Amniotic Fluid Cells to Express Insulin
Human amniotic fluid cells could be reprogrammed to express key beta cell proteins, however insulin gene expression was insufficient to reverse hyperglycemia in diabetic animals. [Differentiation]

Methotrexate Reduces the Incidence of Severe Acute Graft versus Host Disease Without Increasing the Risk of Relapse After Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors
Data suggest that methotrexate reduces the incidence of severe acute graft versus host disease without increasing the risk of relapse but with an accompanying trend toward improved survival after unrelated reduced-intensity transplantation with antithymocyte globulin in the conditioning regimen. [Biol Blood Marrow Transplant]

Effects of Neuropeptide Substance P on the Expression of Adhesion Molecules in Cord Blood Hematopoietic Stem Cells
Researchers aimed to assess the role of Substance P along with a cytokine cocktail on cord blood CD34+ adhesion molecule expression. [Ann Hematol]

Mesenchymal Stem Cells Negatively Regulate Dendritic Lineage Commitment of Umbilical Cord Blood-Derived Hematopoietic Stem Cells: An Unappreciated Mechanism as Immunomodulators
Results demonstrate that differentiation of hematopoietic stem cells into mature dendritic cells is inhibited in the presence of mesenchymal stem cells. [Tissue Eng Part A]

Umbilical Cord Blood CD45+/CD34+ Cells Coexpression in Preterm and Full-Term Neonates: A Pilot Study
Researchers sought to compare the coexpression of human umbilical cord blood CD45+/CD34+ cells in preterm and full-term neonates. [J Matern Fetal Neonatal Med]

Further Improve Hematopoietic Progenitor Proliferation
with Human LDL
by STEMCELL Technologies

ORDER NOW

INDUSTRY NEWS

Gamida Cell-Teva Joint Venture Receives FDA Fast Track Designation for StemEx® for Leukemia and Lymphoma
Gamida Cell announced that the Gamida Cell-Teva Joint Venture has received a Food and Drug Administration (FDA) Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma. [Gamida Cell Press Release]

Valeant and Biovail Agree to Merge
Valeant and Biovail announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc. [Biovail Corporation Press Release]

SEK 100 Million for Research into Regenerative Medicine
Karolinska Institutet has received a grant of SEK 100 million from the Knut and Alice Wallenberg Foundation for a regenerative medicine research centre - the Wallenberg Institute for Regenerative Medicine. [Karolinska Institutet Press Release]

FDA Approves Tasigna® for Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demonstrate Major Advance Over Glivec®
The U.S. Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. [Novartis Pharmaceuticals Press Release]

Pfizer Pulls Leukemia Drug from U.S. Market
Drugmaker Pfizer, Inc. is pulling a decade-old leukemia medicine, Mylotarg, off the U.S. market after a study found a higher death rate and no benefit for patients. [Reuters]

POLICY NEWS

National Heart, Lung, and Blood Institute Funds Research to Improve Safety of Red Blood Cell Transfusions
The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. [The National Heart, Lung, and Blood Institute, United States]

New Videos Reveal How NIH Identifies the Most Promising Research Applications
The National Institutes of Health's (NIH) Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States]

FDA Told to Step Up Oversight of Offshore Clinical Trials
The Food and Drug Administration (FDA) hasn't done enough to monitor clinical trial data coming from overseas sites and patients, which increasingly dominate the studies used to support U.S. drug applications, according to a report from the Department of Health and Human Services' inspector general. [Department of Health and Human Services, United States]

FDA Pushes Orphan Drug Research
The Food and Drug Administration (FDA) published a list of 235 treatments that may have benefit in rare disorders and already have marketing clearance for other uses. [Food and Drug Administration, United States]

President of EFPIA Calls for a ‘New Dialogue’ on Medicines
Andrew Witty, CEO of GlaxoSmithKline and President of European Federation of Pharmaceutical Industries and Associations (EFPIA), the body representing the research-based pharmaceutical industry in Europe, called for ‘a new dialogue’ between governments and the pharmaceutical industry in order to deliver patient access to better medicines and enhance Europe’s competitiveness as a base for R&D investment. [European Federation of Pharmaceutical Industries and Associations, European Union]

Publication of New Enforcement Strategy
A new enforcement strategy has been published by the Inspection, Enforcement and Standards Division. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

FDA/CDRH Public Meeting: Oversight of Laboratory Developed Tests [Food and Drug Administration, United States]

July 26-27, 2010: Meeting of the Blood Products Advisory Committee Announcement [Center for Biologics Evaluation and Research]

Risk Evaluation and Mitigation Strategy Public Meeting [Center for Biologics Evaluation and Research, United States]

National Human Genome Research Institute; Notice of Closed Meeting [National Institutes of Health, United States]

Presentations About the Regulation of Blood and Tissues [Therapeutic Goods Administration, Australia]

EVENTS

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

International Society for Cellular Therapy – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) - Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

International Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

AABB (formerly known as the American Association of Blood Banks) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010
October 9-12, 2010
Baltimore, United States

Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

World Cord Blood Congress
November 4-7, 2010
Marseille, France

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Senior Scientist - Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe - Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cord Blood News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Cord Blood News: Archives | Events | Subscribe | Contact Us

Suite 201 - 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada